Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

Phase 4

Completed

• Conditions: Ischemic Heart Disease
• Interventions: Drug: Regadenoson

• Registration Number: NCT01779869
• Lead Sponsor: Washington University School of Medicine

Brief Summary

The objective for this pilot study is to develop an optimized, clinically usable myocardial PET-MR perfusion protocol and to determine which of all data potentially available should be acquired for a clinical myocardial perfusion examination. Hypothesis: The hypothesis is that high resolution, high sensitivity DCE MRI could replace the rest PET myocardial perfusion imaging, significantly decreasing examination time and patient radiation dose while maintaining the comprehensive reference-quality PET myocardial stress perfusion coverage.

The primary outcome will be comparison of diagnostic accuracy of each combination of imaging to detect clinically significant coronary artery stenosis (≥70% diameter stenosis).

Detailed Description

Simultaneous acquisition PET-MRI is a new technology that has the potential to significantly impact diagnostic patient care. It combines high signal resolution MRI anatomic imaging and PET biological measurements, with the added benefit of radiation dose reduction in comparison to PET-CT. As the incidence of false positive SPECT-MPI studies secondary to attenuation artifact is relatively high and MRI coverage of the left ventricular myocardium is limited, it is likely that one of the immediate applications of PET-MRI technology is myocardial ischemia assessment.

PET has long been considered the noninvasive reference standard for myocardial perfusion. However, delayed contrast enhanced (DCE) MRI is very sensitive for infarct detection. Indeed, both PET and MR imaging have the potential to provide comprehensive whole heart ischemia and infarct detection.

PET-MR technology, with its ability to obtain simultaneous perfusion information via both PET and MRI, has the potential to obtain multiple, possibly redundant, data sets. On the other hand, it also has the potential to combine the best of both techniques to provide a highly robust examination that is both shorter and of lower radiation dose than the standard myocardial PET perfusion examination. Optimization of a protocol is necessary to develop a comprehensive protocol without redundancy. Because of its single injection capability, regadenoson is ideally suited to a protocol that will assess and employ dual-modality myocardial perfusion data collection.

It is expected that the best candidates for PET-MR myocardial perfusion imaging will likely be a) patients whose body habitus suggests that their SPECT-MPI examination would be limited by attenuation artifact -- women with large breasts and patients (usually men) with abdominal obesity and/or b) patients who may have a smaller region of ischemia that might be missed on an MRI examinations with limited perfusion coverage.

Study Timeline

• Study Start: 2013-01
• Study First Submitted: 2013-01-23
• Study First Submitted QC: 2013-01-27
• Study First Posted: 2013-01-30
• Primary Completion: 2015-06
• Study Completion: 2015-06
• Results First Submitted: 2018-01-21
• Status Verified: 2018-05
• Results First Submitted QC: 2018-05-15
• Last Update Submitted: 2018-05-15
• Results First Posted: 2018-06-15
• Last Update Posted: 2018-06-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Patients who have had a clinically ordered rest/regadenoson single-isotope SPECT-MPI study within 10 days prior to cardiac PET-MRI examination
• Reversible perfusion abnormalities on SPECT imaging in at least 2 contiguous myocardial segments
• Patients for whom standard of care coronary ICA is planned

Read More

Exclusion Criteria

• An clinical event (ie; worsening angina pectoris or myocardial infarction) occuring after the SPECT-MPI and before the cardiac MRI examination
• Myocardial revascularization occuring after the SPECT-MPI and before the cardiac MRI examination
• Contraindications to MR imaging (pacemaker, brain aneurysm clips, shrapnel, etc.)
• Renal insufficiency (GFR < 60 mL/min/1.73m2)
• Allergy or other contraindication to gadolinium-based MR contrast agent
• Second or third degree atrioventricular (AV) block
• Active asthma
• Seizures
• Current hypotension (<100/60)
• Current hypertension (>160/90)
• Pregnancy
• Breast feeding
• Use of caffeine, nicotine or over the counter cold medicines within 12 hours of the cardiac PET-MRI examination
• Use of the medication dipyridamole within 48 hrs of the cardiac PET-MRI examination

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single group assignment - imaging	Regadenoson	All patients will undergo PET-MR myocardial perfusion imaging during rapid intravenous administration of 0.4 mg regadenoson.

Primary Outcome Measures

Name	Time	Method
Diagnostic Accuracy of Cardiac PET/MRI Examination	PET/MRI imaging was performed within 10 days after SPECT-MPI examination	The accuracy of the cardiac PET and cardiac MR examination components of the PET/MRI, and the accuracy of the combined PET/MR examination, for ischemic heart disease will be compared to the accuracy of cardiac SPECT in patients who have had ICA as "truth" or the reference standard. To assess the accuracy of an abbreviated PET/MR examination, an additional accuracy analysis was made using only the stress PET perfusion imaging and the MR LGE data sets. The accuracy of this combined data set was also determined with ICA as "truth" or the reference standard. Accuracy is calculated as % difference = (experimental - true) x 100%.

Trial Locations

Locations (1)

Center for Clinical Imaging Research at Washington University School of Medicine; 🇺🇸 Saint Louis, Missouri, United States